Previous Close | 13.12 |
Open | 13.11 |
Bid | 12.95 x 1400 |
Ask | 13.46 x 800 |
Day's Range | 13.08 - 13.12 |
52 Week Range | 11.43 - 13.22 |
Volume | |
Avg. Volume | 156,209 |
Market Cap | 462.246M |
Beta (5Y Monthly) | 0.61 |
PE Ratio (TTM) | 7.41 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 1.49 (11.33%) |
Ex-Dividend Date | May 14, 2024 |
1y Target Est | N/A |
BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) (5LB: FRA) ("BioVaxys" or "the Company"), is pleased to announce that it has further extended its research collaboration with The Ohio State University ("The Ohio State") for SARS-CoV-2, SARS-CoV-1, and pan-sarbecovirus vaccine research. This is the second twelve-month extension of the research collaboration between BioVaxys and the University since 2021.